E komo mai kakou! Welcome everyone!

One rule in life is “Change is an inevitable occurrence”. 2018 is no exception to the rule and will present us with many new challenges and uncertainties. What remains unchanged is the commitment of American Society of Clinical Laboratory Science-Hawaii (ASCLS) and Clinical Laboratory Management Association (CLMA) Aloha Chapter to support all clinical laboratory employees throughout the State of Hawaii. This year we are committed to presenting another quality conference which will be highly informative and entertaining.

Volunteer committee members have been working diligently over the past 9 months to ensure another outstanding conference. The program is filled with nationally recognized speakers and local experts. A “sold-out house” of exhibitors are waiting to share their latest technologies and updates regarding clinical laboratory processes and testing methodologies. Along with the abundant amount of delicious food, we invite attendees to enjoy the two days of informative sessions and networking with fellow laboratorians. Please express your appreciation to our sponsors, vendors, local laboratories and employers who make this annual meeting possible. A special thank you goes out to all the volunteers who started planning this conference months ago. Please help us thank the following individuals for donating their valuable time to make this conference possible:

Registration: Gale Fujitani (Kaiser, retired), Jennifer Baba (DLS)Facilities: Lynne Ramirez (Tripler, retired), Rob Lahoe (Kaiser)Exhibits: Eben Chun (PACRIM) Finance: Glenda Pangelinan (CLH), Linda Sakuda (Tripler, retired)PACE Coordinator: Susan Taura (DLS)Program: Chairperson: Ryan Tsuji (Kuakini), Sheri Gon (UH – MT Program), Glenda Pangelinan (CLH), Claire Muranaka (DLS), Susan Naka (DOH), Blane Nagareda (Kaiser), Michael Lieberman (ASM), Marcella Yee (Tripler), Jane Tansiongco (Pali Momi Med Cntr), Shana Gaug (KMCWC)Website and Mobile App: Leslynne Perry (DLS), Kristen Croom (Queen's), Rayna Hirata (Kaiser)

The board members of ASCLS Hawaii and CLMA Aloha Chapter are very interested in hearing from you. They will be present throughout the 2-day conference. Please introduce yourselves to them. They would love to "talk story" and hear your ideas and concerns.

Thank you for making this another successful year. The success of this conference is dependent on your support and participation.

Aloha nui,

Garan Ito Lynne RamirezPresident, CLMA Aloha Chapter President, ASCLS Hawaii

2

2018 HAWAII CLINICAL LABORATORY CONFERENCE

GENERAL INFORMATIONWebsite www.HiClinLabConference.org

Registration Registration Desk, located in the lobby of the Honolulu Country Club

Wednesday, May 16, 2018

Thursday, May 17, 2018

7:30 a.m. – 10:00 a.m.11:30 a.m. – 5:00 p.m.

7:30 a.m. – 10:00 a.m.11:30 a.m. – 4:00 p.m.

Lunch Wednesday, May 16, 2018 11:30 a.m. – 1:30 p.m.

Thursday, May 17, 2018 11:30 a.m. – 1:30 p.m.

Exhibits Main Dining Room

Wednesday, May 16, 2018

Thursday, May 17, 2018

11:30 a.m. – 5:30 p.m.

11:30 a.m. – 3:30 p.m.

ASCLS Business Meeting

Heavy Pupus will be served.

Come for information on upcoming ASCLS events

Thursday, May 17, 2018 5:30 p.m. – 7:00 p.m.

3

Workshop #1 IntermediateSubject Area – Hematology Wednesday, May 16 8:00 – 9:30 am 1.5 Contact Hours

Hemophilia - The Disease and the Tests, All Mixed Up

Jim DeMaseSr. National Technical Sales ManagerPrecision BioLogic Inc. Dartmouth, Nova Scotia, CANADA

Hemophilia is a disease that strikes rich and pour, royals or commoners. We will review the types, symptoms, and diagnosis and common treatment options available today. The laboratory testing methods and their clinical applications in laboratory test diagnosis will be outlined and new recombinant factor replacement products will be highlighted as they pose new challenges for the hemostasis lab. Case studies will be used to relate to real world situations.

Objectives: 1. Describe the types of Hemophilia that affect patients.2. Explain the range of Hemophilia symptoms along with diagnosis and treatment. 3. Relate the methods and clinical applications for mixing studies and factor inhibitors.

Workshop #2 IntermediateSubject Area – Hematology Wednesday, May 16 8:00 – 9:30 am 1.5 Contact Hours

The Expanded CBC in Hematology: How Immature Cell Counts Help Complete the Patient Picture

Robert OleksySenior Clinical SpecialistSysmex

The clinical utilization of immature cell counts used in conjunction with mature cell count data may assist clinicians with assessing pathophysiological mechanisms and help complete the overall patient picture. This session will discuss newer hematology parameters currently available to clinicians outside of the standard Complete Blood Count (CBC). The presentation will include information on Immature Granulocyte (IG) percent and absolute counts, Reticulocyte Hemoglobin content, Immature Platelet Fraction (IPF) and Immature Platelet Count (IPC). The review will include clinical evidence and case studies related to the parameters and discuss the impact the authors found in their studies.

Objectives:1. Describe novel hematology parameters and their derivation.2. Investigate the evidence for their clinical utility.3. Discuss how new information can be applied to patient care.

4

Workshop #3 IntermediateSubject Area – Immunology Wednesday, May 16 8:00 – 9:30 am 1.5 Contact Hours

Primary Immunodeficiency Disease: Underdiagnosed at any age

Dr. Anne Sherwood, PhD.Director of Scientific AffairsThe Binding Site, Inc.San Diego, CA

Primary Immunodeficiency Diseases (PID) are inborn, genetic disorders with defects in one or more components of the immune system. There are over 180 disease states associated with PID, and they are often underdiagnosed due to the level of severity of the immune dysfunction. Categories of PID, the various methods of testing involved, and economic impact of lack of diagnosis will be discussed.

Objectives:1. Identify the difference between primary and secondary immunodeficiency and define categories of

Primary Immunodeficiency Diseases (PID).2. Describe testing methodology for determining presence of a PID.3. Discuss potential economic impact of lack of diagnosis of a PID.

Workshop #4 BasicSubject Area – General Wednesday, May 16 8:00 – 9:30 am 1.5 Contact Hours

Why Knowing Now Matters in the Emergency Department

Dr. Ellis Jacobs, PhD, DABCC, FACB Director, Scientific AffairsAbbott Rapid Diagnostics

There have been significant increases in emergency room visits across the US and delays in the ED leads to poor outcomes. There is an association between waiting times and short-term mortality and hospital admission. Laboratory turnaround time can impact ED operations and, based on simulation modeling, the best performance is predicted when the TAT is 40 minutes or less. The needs of every ED are different and this presentation will look at the impact of Point of Care testing on the provision of medical care and ED operations in three clinical conditions: chest pain (cardiac), sepsis (critical care) and infectious diseases.

Objectives:1. Understand the association between ED waiting times and short-term mortality and hospital

admissions.2. Describe the operational benefits that can be achieved with a rapid chest pain disposition protocol.3. Understand the role of lactate in the identification and monitoring of sepsis.4. Explain the impact on key ED operational metrics of rapid infectious disease testing.

5

Workshop #5 IntermediateSubject Area – Blood Bank Wednesday, May 16 10:00 – 11:30 am 1.5 Contact Hours

Using Molecular Testing to Improve Transfusion TherapyDr. Ingrid Perez-Alvarez, MD Assistant Professor of PathologyUC Irvine Medical Center, California

Management of patients with difficult serologic laboratory findings can be challenging for the transfusion service and the blood donor centers, both from the diagnostic standpoint as well as when providing matched red cell units in a timely manner becomes an issue. This session will cover the applications of red cell genotyping to blood donor extended red cell antigen phenotype prediction and how it can help to establish a readily available inventory of highly matched red cell units. Red cell genotyping applied to the management of patients who are both alloimmunized or at risk for alloimmunization, those with complex serologic findings, and pregnant patients at risk for hemolytic disease of the fetus and newborn will be discussed. This session will be valuable to bench technologists and supervisors of the transfusion medicine service and blood donor center. Objectives:

1. Describe the laboratory technologies available for RBC genotyping and its limitations. 2. Explain how red cell genotyping can help in the blood bank management of multiply transfused

patients, patients with autoantibodies, and patients with complex serologic laboratory findings. 3. Discuss how red cell genotyping can help in the blood bank management of pregnancies complicated

by hemolytic disease of the fetus and newborn by anti-D and other minor red cell antigen antibodies. 4. Explain how red cell genotyping can be used in blood collection facilities to establish an inventory of

readily available extended typed red cell units to provide selection of highly matched red cell units for recipients who are alloimmunized or at risk for alloimmunization.

Workshop #6 IntermediateSubject Area – General Wednesday, May 16 10:00 – 11:30 am 1.5 Contact Hours

Impact of High Sensitivity Troponin in Acute Coronary Syndrome and Non-Acute Coronary Syndrome

Theresa JosephMedical Scientific LiaisonRoche Diagnostics Corporation

The advent of high sensitivity Troponin in the U.S. has changed the landscape of cardiac testing, in terms of clinical and analytical considerations. This session will include discussion of current literature related to Acute Coronary Syndrome and other causes of Troponin elevation. Differences between “contemporary” and “high sensitivity” Troponins will also be discussed.

Objectives:1. Describe the history of biomarkers utilized in cardiac disease 2. List 3 clinical conditions that can cause elevations in Troponin 3. Explain the rationale behind serial Troponin testing in Acute Coronary Syndrome 4. List 3 differences between “contemporary” and “high sensitivity” Troponins

6

Workshop #7 Basic Subject Area –Safety Wednesday, May 16 10:00 – 11:30 am 1.5 Contact Hours

Controlling the Human Risk FactorSean G. Kaufman, MPHCEO and Founding PartnerSafer BehaviorsSponsored by: CLMA – Aloha Chapter

Until human beings are replaced by robots, the greatest risk in the laboratory will not be what is worked with – rather who is working with it and the collective practices (culture) of those working with it. You must be human to attend this session - as that is a prerequisite for all human risk factors discussed during this session. Upon completion of this session, participants will be able to discuss several human risk factors, identify strategies for controlling these human risk factors, and directly apply human risk factor controls upon returning to their organizations. Being human is a risk and this discussion will discuss those risks.

Objectives:1. Discuss the impact of human risk factors on laboratory safety. 2. List several human risk factors. 3. Describe controls for several human risk factors. 4. Apply human risk factor controls within organizational settings.

Workshop #8 BasicSubject Area – Management Wednesday, May 16 10:00 – 11:30 am 1.5 Contact Hours

Patient Safety: A Quality System Approach to POCT QC/QA

Dr. Ellis Jacobs, PhD, DABCC, FACBDirector, Scientific Affairs Abbott Rapid Diagnostics

There are multiple QA issues with POCT and, due to the rapid availability of results, POCT data can be seen and acted upon prior to the application of QC checks or other external mechanism for assuring the validity of test results. Most errors in laboratory testing are pre-analytical in nature, followed by post-analytical; with only 15% occurring during the analytical phase. However, in POCT, despite an overall reduction in errors, the majority of errors occur in the analytical phase. POCT technology has evolved to the level of autonomation, intelligent automation that detects single point failures and automatically stops the analytical process. Never the less, QC procedures are an essential part of the Quality Management System and must be able to detect mistakes to enable immediate correction. It is necessary that the sources of error in the POCT analytical process be identified and an individualized quality control plan be developed that mitigates the risks of error to acceptable levels.

Objectives:1. To understand what a Quality Management System is and what Quality System Essentials are. 2. To be able to describe the influence of POCT on the probability of occurrence of pre-analytical, analytical

and post-analytical errors. 3. Understand the nature of QC procedures and be able to describe the differences between surrogate and non-

surrogate Quality Control. 4. To be able to explain the critical factors to consider when deciding the appropriate POCT QC system to

implement

7

Workshop #9 IntermediateSubject Area - General Wednesday, May 16 1:30 – 3:00 pm 1.5 Contact Hours

The Natriuretic Peptides: Utilization In Heart Failure and Co-Morbidities

Theresa Joseph Medical Scientific Liaison Roche Diagnostics Corporation

The natriuretic peptides (NT-proBNP and BNP) have long been recognized as aids in the diagnosis and prognosis of heart failure. Recent literature demonstrates their utilization in clinical conditions outside of heart failure. This session will cover mechanisms of release of the natriuretic peptides, the pathophysiology of heart failure, and other disease states that result in elevations of these cardiac biomarkers.

Objectives:1. Describe the structure, mechanisms of release, and actions of the natriuretic peptides 2. Describe normal cardiac function and the pathophysiology of heart failure 3. List 3 clinical conditions outside of heart failure that cause elevations in the natriuretic peptides

Workshop #10 IntermediateSubject Area – Management Wednesday, May 16 1:30 – 3:00 pm 1.5 Contact Hours

The Future of Value-Based Payments For Healthcare and Laboratories

Dr. Brian Jackson, MD Associate Professor of Pathology (Clinical), University of Utah ARUP Laboratories and University of Utah

Payment systems for healthcare within the U.S., both public and private, are widely acknowledged to be a significant impediment to improving overall value. Fee-for-service encourages overuse of resources; capitated arrangements lead to fears of underuse; and control mechanisms such as prior authorization inhibit access and lead to frustration and inefficiency. The co-existence of multiple competing payment systems is challenging to provider organizations such as clinical labs and inhibits innovation. This lecture will discuss the impact of different payment systems and possible future directions and their impact on laboratories.

Objectives:1. Describe the unintended consequences of both fee-for-service and capitated payment models 2. Identify different mechanisms used by payors to regulate utilization under fee-for-service 3. Identify the major characteristics of so-called “value-based” payment models under CMS 4. List challenges of measuring quality within “value-based” payment models

8

Workshop #11 BasicSubject Area – Microbiology Wednesday, May 16 1:30 – 3:00 pm 1.5 Contact Hours

Antimicrobial Resistance in Hawaii?

Dr. Amy M. Woron , Ph.D. Deputy Chief for Antimicrobial ResistanceState Laboratories Division State of Hawaii Dept of Health

Caitlin Cook, MPHAntimicrobial Resistance CoordHawaii Dept. of Health

Superbugs in paradise? Antimicrobial resistance has been at the forefront of national attention since the release of the National Action Plan for Combating Antibiotic-Resistant Bacteria. This session will provide a history of the Antimicrobial Resistance Laboratory Network (ARLN) and describe how Hawaii fits into the national surveillance plan. The focus will be on laboratory and epidemiology initiatives within Hawaii’s surveillance system for emerging multi-drug resistant organisms including the interaction between health care facilities, reference laboratories, and public health.

Objectives:1. Describe the antimicrobial resistance surveillance system in Hawaii and how it fits into the national

system. 2. Identify specimens that meet criteria for entry into the antibiotic resistance laboratory network

(ARLN). 3. Discuss collaboration with public health on colonization investigations

Workshop #12 BasicSubject Area – General Wednesday, May 16 1:30 – 3:00 pm 1.5 Contact Hours

IQCP- What does it mean to you?

Christine Arruda, MT(ASCP) Critical Care Sr. Product Marketing Manager Siemens Healthcare Diagnostics Inc.

CLIA introduced a voluntary quality control policy in January 2014. This was available for all non-waived tests with the exception of pathology. The individual quality control plat (IQCP) was an alternate option from CLIA regulations. Since its introduction many facilities have implemented this as a means to identify potential failures and errors around specific testing. During this workshop we will review the three steps for the development of an IQCP along with what is needed to cover the entire testing process. We will also review specific examples of how additional regulatory agencies review and IQCP.

Objectives:1. Describe the three components of developing a Quality Control Plan 2. Identify the categories that are included in the risk assessment 3. Recognize what is available for guidance on implementing a IQCP

9

Workshop #13 IntermediateSubject Area – Hematology Wednesday, May 16 3:30 – 5:00 pm 1.5 Contact Hours

The Bone Marrow is talking to us. Is your current WBC listening?Robert OleksySenior Clinical SpecialistSysmex

Current automated methods of cell enumeration offer accurate and precise counts of cell populations versus data obtained via manual methodology. This session will discuss the clinical and operational advantages and limitations of currently available hematology parameters such as WBC, ANC, Immature Granulocytes (IG’s) and band counts. The review will include clinical evidence and case study examples related to these tests and discuss the impact the authors found in their studies.

Objectives:1. Describe current and novel hematology parameters and their derivation2. Investigate the evidence for their clinical and operational utility.3. Discuss how new information can be applied to patient care.

Workshop #14 IntermediateSubject Area – Microbiology Wednesday, May 16 3:30 – 5:00 pm 1.5 Contact Hours

Dengue Virus-Specific Humoral and Cellular Immune Responses to Vaccination and Natural Infections in HumansDr. Wei-Kung Wang, M.D., Sc.D. Professor Department of Tropical Medicine, Medical Microbiology and Pharmacology John A. Burns School of MedicineUniversity of Hawaii at Manoa

The four serotypes of dengue virus (DENV) are the leading cause of mosquito-borne viral disease in humans. It has been estimated that approximately 390 million infections occur annually worldwide. Most DENV infections are inapparent, and about 25% of infections cause clinical diseases ranging from a self-limited illness, dengue fever, to severe and potentially life-threatening disease, dengue hemorrhagic fever/dengue shock syndrome. These were classified as dengue, dengue with warming signs and severe dengue according to the WHO revised case definition. While several candidate DENV vaccines are in different phases of clinical trials, only one DENV vaccine, Dengvaxia from Sanofi Pasteur, a live-attenuated chimeric yellow fever-dengue tetravalent dengue vaccine, has been licensed. Its overall moderate efficacy (~60%), lower efficacy among dengue-naïve compared with dengue-experienced individuals (~40% vs. ~80%), and increased risks of hospitalization and severe dengue among young children highlight the need for a better understanding of humoral and cellular immune responses following natural DENV infections and vaccination. As the major target of antibody responses after DENV infection, the envelope protein is the main focus for dengue vaccine development and serological tests. We review recent progress on human monoclonal antibodies against DENV, epitopes recognized by potent neutralizing monoclonal antibodies, polyclonal sera and B-cells as well as CD4 and CD8 T-cell responses following natural DENV infections and vaccination. This information

10

would provide new insights into a safe and effective dengue vaccine and distinction between natural infections and vaccination. Objectives:

1. List the mosquito-borne viruses causing significant human diseases.2. Name the only dengue vaccine that is currently licensed and describe the components of this vaccine. 3. Explain the major concerns with the use of this vaccine. 4. Identify the main problems of current serological tests for flaviviruses.

Workshop #15 IntermediateSubject Area – Management Wednesday, May 16 3:30 – 5:00 pm 1.5 Contact Hours

TJC/CAP/COLA Inspection ReadinessDr. Sharon Ehrmeyer Ph.D., MT(ASCP) University of Wisconsin-Madison

For those managers, supervisors, POCCs, medical laboratory scientists thinking about or preparing for inspection, this session is for you! The latest accreditation TJC, CAP, and COLA requirements are addressed along with how to avoid the common inspection deficiencies and pitfalls cited. Techniques are discussed to identify and correct problems before the inspector arrives and surefire strategies are reviewed to aid sites in successfully complying with the numerous, and often confusing, accreditation requirements. Following the do’s and don’ts of inspection readiness, participants will gain confidence in meeting surveyors/inspectors.

Objectives:1. Identify the latest accreditation requirements that specifically impact your testing situation 2. Discuss common deficiencies and pitfalls cited by your accrediting agency3. Develop strategies to identify and correct problems to avoid inspection failures 4. Integrate session information to create an appropriate game plan for meeting the surveyor/inspector

with confidence

Workshop #16 BasicSubject Area – General Wednesday, May 16 3:30 – 5:00 pm 1.5 Contact Hours

Driving Quality Measure Improvements for Your Diabetic Population with Point of Care Solutions.Maria Peluso-Lapsley. MBA Chronic Diseases - Sr. Product Marketing Manager Siemens Healthcare Diagnostics Inc.

Diabetes is one of the leading and most costly chronic diseases. Poor diabetes control, along with major diabetes complications, costs the healthcare system billions of dollars per year. The ultimate goal is to deliver comprehensive care and help patients control their diabetes and prevent complications associated with the disease. In this workshop, you will learn about point of care solutions that can be deployed at the time of visit for driving and improving quality measures associated with comprehensive diabetes care.

Objectives:1. Discuss the quality measures for delivering comprehensive diabetes care 2. Identify the point of care solutions that can impact key measures

11

3. Review examples of successful programs 4.

Workshop #17 BasicSubject Area – General Wednesday, May 16 5:30 – 7:00 pm 1.5 Contact Hours

CSI HONOLULU II

Doryn Matsuda Evidence Specialist HPD Forensic Laboratory

Gavin YuasaCriminalistC&C of Honolulu/C&C of Honolulu

Charlotte CarterMedical Examiner InvestigatorMedical Examiner’s Office

Crime happens all the time. Throughout time, the sciences that we are all familiar with, medical, chemical, or physical, have all played an integral role in helping solve criminal acts both small and large. This presentation will highlight the significance of the sciences in the field of criminal investigation as investigators work to unravel the mystery of a crime.

Objectives:1. Identify the principles of a crime scene and a death investigation.2. Discuss the principles and analysis of physical evidence.3. Illustrate the interrelationship of all units to come to a final conclusion (final product).

Workshop # 18 BasicSubject Area – Management Wednesday, May 16 5:30 – 7:00 pm 1.5 Contact Hours

EXCEPTIONAL SERVICE BASED ON PRINCIPLES

Chérie V. Petersen Distance Education Program Coordinator Institute for Learning, ARUP Laboratories

As customers ourselves, we all know great customer service when we see it or experience it. However, really describing exactly what it is or nailing down its particular elements possess a much more challenging task. What does good customer service look like, sound like, feel like, and what kinds of things make for a positively memorable experience? And if by chance you can figure all of that out, how do you go about applying the principles of great service in order to meet the specific needs of your unique customer types? This session will define the principles of great customer service as well as what constitutes a great service experience. Objectives:

1. Recognize the factors that contribute to a great customer service experience. 2. List specific principles for delivering exceptional service. 3. Apply customer service skills based on unique customer needs. 4. Describe some of the intangible aspects of great customer service.

12

Workshop #19 IntermediateSubject Area – Management Wednesday, May 16 5:30 – 7:00 pm 1.5 Contact Hours

A Hippocratic oath for the diagnostic industry: How the sustainability movement will reward healthcare businesses for doing the right thingDr. Brian Jackson, MD Associate Professor of Pathology (Clinical), University of Utah ARUP Laboratories and University of Utah

Within the United States, there is a cultural divide between healthcare professionals who operate within the framework of medical/scientific norms and ethics, and healthcare product and services corporations who operate within the framework of laissez-faire capitalism. This leads to all kinds of negative effects, from profiteering to maldistribution of resources, and patients suffer the consequences. There is a way to bridge this divide, though. The corporate sustainability movement, which started with environmentalism and has since spread to Wall Street, is creating structures and systems to reward companies for acting in socially responsible ways. This presentation will describe ways in which the clinical laboratory industry can tap into this movement to collectively improve value for our patients.

Objectives:1. Express the key elements of medical ethics and scientific ethics 2. Identify the major stakeholder groups of healthcare corporations 3. Describe the key elements required to achieve a virtuous cycle of corporate sustainability 4. List ways that healthcare organizations and laboratories can partner with their suppliers to improve overall value from both a medical and scientific perspective

Workshop #20 BasicSubject Area – General Wednesday, May 16 5:30 – 7:00 pm 1.5 Contact Hours

From the Line to the Lab: Vascular Access Device Blood CollectionSusan CsatariRN, Clinical Practice ConsultantBD-Canada Preanalytical Systems

The 2016 revision to the INS (Infusion Nurses Society) “Infusion Therapy Standards of Practice, Standard 43: Phlebotomy”, includes significant practice change recommendations for nurses who collect blood samples. This will be reviewed in the context of current common practice, types of vascular access devices in use, and the impact of practice and devices on specimen quality and test results. A key change is new guidance to avoid taking blood from IVs whenever possible, due to high rates of hemolysis associated with these collections. At times, this may result in increased requests for Lab personnel to do venipuncture collections. Up to 85% of clinical therapies are based on lab test results therefore it is essential to ensure that blood specimens are an accurate reflection of the patient’s in vivo status. Given their shared accountability for patient outcomes related to blood collections, it is important for both Lab and Nursing professional to understand each other’s practice and regulatory requirements.ˡPlebani M, Carraro P. Mistakes in a stat laboratory: types and frequency. Clin Chem 1997;43:1348-1351

Objectives:1. Understand changes in Nursing Clinical standards for blood collection and the challenges associated with

changing current practice2. Discuss the aspects of preanalytical best practice that are not commonly understood by nurses who collect blood

13

3. Recognize various types of vascular access catheters commonly used by nurses for blood collection and their impact on specimen quality

Workshop #21 BasicSubject Area – Safety Thursday, May 17 8:00 – 9:30 am 1.5 Contact Hours

Building and Sustaining a Culture of Safety

Sean G. Kaufman, MPHCEO and Founding Partner Safer BehaviorsSponsored by: CLMA-Aloha Chapter

There is a difference between safety climate and culture. One you can see and the other you cannot. It is not what you can see which poses the greatest safety challenge – it is what you cannot see which does. This session will discuss the differences between safety climate and culture, will highlight common risks, rules, and rituals needed to build and sustain a culture of safety. Upon completion of this program, participants will be able to list behavioral expectations for safety officers, leaders, and laboratory staff. Additionally, participants will be able to differentiate expectations and accountability – defining responsible leadership while understanding aspects of human motivation.

Objectives1. Differentiate safety climate and culture. 2. Discuss common risks, rules, and rituals. 3. Define responsible leadership. 4. List behavioral expectations for leaders, scientists, and safety officers.

Workshop #22 IntermediateSubject Area - Chemistry Thursday, May 17 8:00 – 9:30 am 1.5 Contact Hours

Procalcitonin (PCT) Use in Sepsis Management and Antibiotic Treatment Decisions

M. Laura Parnas, PhD, DABCC, FAACC Sr. Scientific Affairs Manager Roche Diagnostics Corporation

This session is an overview of sepsis definition, symptoms, diagnostic criteria, and treatment. We will review clinical evidence of procalcitonin utility in diagnosis, prognosis, progression risk assessment, and guiding antibiotic treatment decisions in sepsis patients and discuss the application of procalcitonin in clinical routine, including procalcitonin measurements and interpretations of results.

Objectives1. Describe the basic characteristics of sepsis and interpret the current guidelines for sepsis diagnosis and

management 2. Demonstrate knowledge of procalcitonin utility in sepsis diagnosis, monitoring, and treatment

decisions 3. Implement procalcitonin measurement and interpretation in clinical practice.

14

Workshop #23 BasicSubject Area – General Thursday, May 17 8:00 – 9:30 am 1.5 Contact Hours

Hawaii Disaster Medical Assistance Team (DMAT) response to Hurricane Irma

Les Chock Teresa Yamasaki RN, BSN, MHA/EdDirector Regional Infection Control Quality Metrics RN Analyst/Peer ReviewKaiser Permanente Medical Center Kaiser Permanente Hawaii Region

The Hawaii Disaster Medical Assistance Team (DMAT) is a deployable, federal medical team of the National Disaster Medical System (NDMS). All team members are federal (intermittent) employees of the U.S. Department of Health and Human Services. The Hawaii DMAT was activated and deployed for a 14-day mission to Key West Florida and provided medical care to the community following Hurricane Irma.

Objectives:1. Describe the purpose of the Hawaii Disaster Medical Assistance Team (DMAT) 2. List the capabilities of DMAT 3. Discuss the deployment process 4. Understand the operations of a DMAT mission

Workshop #24 IntermediateSubject Area – Hematology Thursday, May 17 8:00 – 9:30 am 1.5 Contact Hours

Hemostasis and Women's Health: Focus on Thrombotic Disorders

Katherine (Katy) Whelchel Technical Sales Representative Diagnostica Stago, Inc

We are not all created equally when it comes to hemostasis and thrombosis. This workshop will outline different disease states affecting women’s health, including venous thromboembolism, antiphospholipid syndrome, pregnancy related thrombocytopenia, and disseminated intravascular coagulation (DIC). We will discuss the clinical guidelines establishing best practices for laboratory diagnosis of these disorders. We will review a few clinical case studies featuring women’s health disorders and laboratory diagnosis.

Objectives1. Present overview of different disease states affecting women’s health, including venous

thromboembolism, antiphospholipid syndrome, pregnancy related thrombocytopenia, and disseminated intravascular coagulation (DIC).

2. Discuss clinical guidelines establishing best practices for laboratory diagnosis of these disorders. 3. Explain case studies featuring women’s health disorders and laboratory diagnosis.

15

Workshop #25 IntermediateSubject Area – Immunology Thursday, May 17 10:00 – 11:30 am 1.5 Contact Hours

Utilization of Serum Free Light Chain Assays in The Diagnosis and Monitoring of Multiple Myeloma

Dr. Anne Sherwood Director of Scientific AffairsThe Binding Site, Inc., San Diego, CA

Patients with multiple myeloma (MM) and related plasma cell disorders often present with a myriad of non-specific symptoms, making diagnosis challenging. Traditional screening methods are insensitive, missing a significant percentage of these patients. The laboratory can play a key role in helping the clinician obtain a more accurate diagnosis with appropriate follow-up by adopting updated MM screening protocols recommended by the International Myeloma Working Group (IMWG) & National Comprehensive Cancer Network (NCCN).

Objectives:1. Compare traditional myeloma testing methods with current recommended protocols and describe how

kappa & lambda free light chain analysis plays a key role.2. Discuss the updated International Myeloma Working Group (IMWG) criteria for diagnosis of Multiple

Myeloma and new recommendations for inclusion in routine practice.3. Explain why it is necessary to monitor both intact immunoglobulin paraprotein and serum free light

chains in multiple myeloma.

Workshop #26 BasicSubject Area – Chemistry Thursday, May 17 10:00 – 11:30 am 1.5 Contact Hours

Biomarkers of Alzheimer’s Disease: Current Perspective and Future Trends

Dr. M. Laura Parnas, PhD, DABCC, FAACCSr. Scientific Affairs Manager Roche Diagnostics Corporation

Alzheimer’s disease is a degenerative brain disease and the most common cause of dementia. This session will provide an overview of Alzheimer’s disease, its definition, symptoms, diagnostic criteria, and management strategies. We will review the current landscape of biomarkers for the diagnosis of Alzheimer’s disease, and close the session with an overview of the current challenges and future opportunities for these biomarkers in clinical practice and routine laboratory operations.

Objectives:1. Describe basic aspects of Alzheimer’s disease pathobiology, current diagnostic criteria, and disease

management strategies 2. Discuss current clinical practice involving Alzheimer’s disease biomarkers 3. Demonstrate knowledge of Alzheimer’s disease biomarkers’ advantages and limitations

16

Workshop #27 BasicSubject Area – Management Thursday, May 17 10:00 – 11:30 am 1.5 Contact Hours

Key Concepts for Leading with Authority

Chérie V. Petersen Distance Education Program Coordinator Institute for Learning, ARUP Laboratories

Leadership positions inherently bear the significant weight of overwhelming responsibility. Having the “responsibility” to lead does not always go hand in hand with having “ability” to lead, meaning having the critical key characteristics and attributes necessary for becoming a great and inspired leader. Leaders who have the ability to cultivate engaged employees, employees who are committed through opportunities to contribute to meaningful work, mission, and vision, don’t just happen without developing specific qualities and attributes that are critical to successful leadership. Attendees of this session will walk away with a new perspective regarding their role as leaders, will look upon their responsibilities with a greater sense of significance, and see opportunities for developing leadership “abilities”, while recognizing their personal and professional impact on the employees they hope to lead, engage, and inspire.

Objectives:1. Define the responsibilities and abilities of great leaders 2. Identify the qualities, characteristics, and behaviors found among great leaders. 3. Understand the key attributes necessary for leading with authority. 4. Develop strategies to build individual authority.

Workshop #28 IntermediateSubject Area – Hematology Thursday, May 17 10:00 – 11:30 pm 1.5 Contact Hours

Direct Oral Anticoagulants; How They Work, How They Can Be Measured, And How They Affect Us in The Coag Lab

Katherine Whelchel Technical Sales Representative Diagnostica Stago, Inc.

Direct Oral Anticoagulants (DOACs) are now considered ‘routine’ anticoagulants in our patient population requiring out-patient anticoagulation. This session will discuss the current methods for monitoring traditional anticoagulants (warfarin, heparin), and the options available for measuring the DOACs. We will examine the impact of these DOACs on both routine and specialty coagulation assays. We will close the session with some case studies highlighting the role of the laboratory in these types of clinical situations.

Objectives:1. Discuss current methods for monitoring traditional anticoagulants (Coumadin, heparin) 2. Demonstrate the impact of direct oral anticoagulants (DOACs) on both routine and specialty assays. 3. Understand the role of the laboratory for this testing regime using case studies

17

Workshop #29 IntermediateSubject Area – General Thursday, May 17 1:30 – 3:00 pm 1.5 Contact Hours

Selecting the Right QC

Dr. Sharon Ehrmeyer Ph.D., MT(ASCP) University of Wisconsin-Madison

Is your QC program in need of review or an update? Are you uncertain as to the number of controls, which rules are best and cost-effective, and how to interpret QC data and respond to out-of-control situations? If so, this workshop will provide you with the latest information to answer these important questions. Participants will select the right QC based on a test method’s performance characteristics and 6-sigma statistics. The techniques provided will change current, arbitrary QC practices into a total quality assessment process for ensuring quality test results.

Objectives:1. Describe a systematic planning process for selecting the “right” QC for test methods 2. Utilize collected method performance validation data to determine the RIGHT QC rule 3. Evaluate and appropriately respond to QC data for corrective actions4. Develop cost effect QC practices based on 6-sigma to ensure quality test results.

Workshop #30 BasicSubject Area – Management Thursday, May 17 1:30 – 3:00 pm 1.5 Contact Hours

A Budding Industry: Growth of Medical Cannabis Testing Labs in Hawaii

Dr. A. Christian Whelen, PhD Carrie Despotovich Chief, State Laboratories Division Aeos LabState of Hawaii Department of Health Honolulu, Hawaii

Caleb King, MS Dr. William A. English, PhDVP Scientific Operations Lab DirectorSteep Hill Hawaii PharmLabs Hawaii LLC

Although Hawaii was one of the first states to legalize medical cannabis in 2000, the 15 years under the Department of Public Safety failed to produce a legal mechanism to acquire products. The Department of Health (DOH) established a dispensary system in 2 years. Part of the system to ensure the safety of patients, products was the requirement for DOH-certified laboratories that would provide contaminant and potency testing. This panel discussion brings together representatives from DOH State Laboratories and community testing laboratories to present perspectives from both sides of the regulatory equation.

Objectives:1. Identify regulated analytes described in HAR 11-8502. Describe the origin(s) of Hawaii medical cannabis testing labs 3. Identify some of the startup challenges that laboratories faced

18

Workshop #31 BasicSubject Area – Microbiology Thursday, May 17 1:30 – 3:00 pm 1.5 Contact Hours

Angiostrongyliasis: Diagnostic and Clinical Challenges

Dr. Kenton Kramer, PhDAssociate Professor, Dept of Tropical Medicine, Med Micro and Pharm John A Burns School of Medicine University of Hawaii

Dr. Vernon Ansdell, MDInternal MedicineKaiser Hawaii Permanente Group

Angiostrongyliasis (rat lungworm disease) is a globally emerging, potentially serious nematode infection caused by Angiostrongylus cantonensis. Historically, it has been described as a rare disease associated with a self-limiting course of infection. Clinical experience in Hawaii, however, suggests that infection may be severe with long-term debilitating consequences and potential fatalities. Patients presenting to the ER are often sent home because angiostrongyliasis wasn't considered in the differential diagnosis. The challenges faced by the medical community in the diagnosis, clinical management and prevention of angiostrongyliasis will be discussed as it relates to the parasite and its life-cycle.

Objectives:1. Explain the global epidemiology of angiostrongyliasis with an emphasis on Hawaii 2. Explain the approaches to the laboratory diagnosis of angiostrongyliasis 3. Explain the clinical diagnosis of angiostrongyliasis 4. Explain the approaches to the clinical management of angiostrongyliasis

Workshop #32 IntermediateSubject Area - Hematology Thursday, May 17 1:30 – 3:00 pm 1.5 Contact Hours

Manual Smear Review

Dr. Delecia LaFrance, MDDirector, Medical Affairs Beckman Coulter, Inc.

Automated hematology analyzers have helped to optimize the workflow of the hematology laboratory, thereby decreasing cost, hands on tech time, and human error. Technology, however, has not yet fully replaced the human eye. The manual review of peripheral blood smears is sometimes required to further evaluate hematology slides. This workshop will use clinical vignettes to explore the role of manual smear review in the hematology workflow and their potential impact on patient management. Clinical presentation, hematology specimen workup using automated analyzers, and triggers of manual smear review will be discussed. The role of manual smear review in generating differential diagnoses, informing other confirmatory laboratory tests, providing prognostic information, and leading treatment-related decisions will also be explained.

19

Objectives:1. Describe the clinical workup that generates specimens sent to the Hematology lab. 2. Discuss the key parameters that trigger a Manual Smear Review. 3. Explain the pros and cons of automated hematology analyzers. 4. Evaluate clinical scenarios and determine if/how they might benefit from Manual Smear Review.

Workshop #33 BasicSubject Area – Anatomic Pathology Thursday, May 17 3:30 – 5:00 pm 1.5 Contact Hours

Impact of Molecular Diagnostic Testing and Screening Guidelines on Women’s Reproductive Health

Dr. Nicole Orazio, PhD Hologic, Inc

Advances in molecular diagnostic technology over the past 40 years has resulted in more accurate diagnosis and treatment of a plentitude of diseases. For pathogenic diseases affecting women’s reproductive health, the greatest impact has been with improvement of nucleic acid amplification tests (NAAT) combined with physician compliance to recommended guidelines based on screening algorithms. One of the most successful examples of this combination of improved testing and routine screening is the continuous reduction in deaths due to cervical cancer since 1955. Part I of this seminar will cover the history of cervical cancer screening (CCS), the current state of screening using cytology (Pap test) and Human Papilloma Virus (HPV) NAAT testing, and a review of recent clinical studies on CCS. Part II will focus on the impact of established and emerging Sexually Transmitted Infections (STIs) on women’s reproductive health. This section will cover the diagnostic tests for STIs, clinical outcomes of untreated STIs as well as the recommended CDC guidelines for STI screening. Lastly, this section will review data from recent studies on resurgence of STIs in both the screening and high-risk populations. The information presented in both parts of this session will provide an overview of how molecular testing, screening guidelines and compliance affect clinical outcomes for women’s reproductive health.

Objectives:1. Describe the causative agent of cervical cancer and the main methods for diagnosis 2. Explain the current recommendations for cervical cancer screening and how they have evolved 3. Identify the clinical outcomes of untreated STIs for women 4. Summarize the CDC screening guidelines for common and emerging STIs

Workshop #34 AdvancedSubject Area – Blood Bank Thursday, May 17 3:30 – 5:00 pm 1.5 Contact Hours

Case Studies: Using the Tools in the Toolbox

Sandra Nance Senior Director, IRL Biomedical Services, American Red Cross, Philadelphia

Even though complex immunohematology cases are uncommon, their appearance is also unpredictable. If it was known which cases would be complex before the patient arrived in the hospital the first time, the

20

provision of blood might be more efficient. However, that is often not possible. In those times, immunohematologists must use their education, experience, testing methods and reagents to investigate and resolve the case. The major focus of the session is to discuss cases that use the tools in the immunohematologists toolbox.

Objectives:1. Discuss case-critical observations and serologic test results. 2. Distinguish case parameters that warrant and require Molecular Studies and Monocyte Monolayer

Assays to determine recommendations for transfusion and including use of the American Rare Donor Program for procurement of product.

3. Critique case-vital results to include in communications to clinicians, physician assistants and transfusion services staff.

Workshop #35 IntermediateSubject Area - Microbiology Thursday, May 17 3:30 – 5:00 pm 1.5 Contact Hours

Forensic Microbiology Related to Corpse Decomposition and Post-Mortem Time Estimation

Dr. David Carter Director and Associate Professor of Forensic Sciences, Forensic Sciences Unit Division of Natural Sciences and Mathematics Chaminade University of Honolulu Honolulu, HI

Medicolegal death investigation plays a critical role in our public health and justice systems. The primary goals of every death investigation are to identify the deceased, establish cause of death, and notify the next of kin. Circumstances can arise, however, where meeting these goals requires an estimate of the time elapsed since death, often referred to as the postmortem interval (PMI). Estimates of PMI are often associated with corpses that have decomposed beyond recognition, so it is used to help identify the deceased. Estimates of PMI may also be used to determine the reliability of an alibi or other statement. A number of approaches have been developed to estimate PMI but none of them are useful in every investigation. Microbial communities, specifically the change in their structure during decomposition, have recently been investigated for their potential as an estimator of PMI because microbes are always present on and in a corpse. Recent research has shown that postmortem microbial communities are dominated by bacterial phyla Actinobacteria, Firmicutes, and Proteobacteria regardless of corpse species, body site, season, and geography. Furthermore, the structure of these communities changes predictably over time. These data show that postmortem microbial communities can be used to estimate postmortem interval with a relatively high level of precision, which has made this area of forensic microbiology one of the most rapidly developing areas of forensic science.

Objectives:1. Discuss the structure and role of medicolegal death investigation in the City and County of Honolulu. 2. Describe the processes associated with the decomposition of remains. 3. Describe the changes observed in the structure of postmortem microbial communities during the

decomposition of remains. 4. Discuss how microbial communities can be used to estimate postmortem interval.

21

Workshop #36 IntermediateSubject Area – Hematology/Microbiology

Thursday, May 17 3:30 – 5:00 pm 1.5 Contact Hours

Viral vs. Bacterial Infection (Using Hematology Parameters)

Dr. Delecia LaFrance Director, Medical Affairs Beckman Coulter, Inc.

The evaluation of patients with infection can be a difficult process, especially in an emergency setting where patients present with nonspecific symptoms that make it difficult to determine the infectious etiology. Nevertheless, this is an important distinction because the treatment can be drastically different, particularly for viral versus bacterial infections. The clinical workup of these patients includes a complete blood count with differential, focusing on elevated lymphocytes as a predicate of viral infection and elevated neutrophils for bacterial infection. Such a traditional approach is fraught with challenges that often necessitates the incorporation of other clinical tests leading to delayed diagnosis and treatment, as well as an increased risk of disease severity and associated complications. This workshop will discuss a novel approach that uses readily available parameters obtained from the hematology analyzer to distinguish between viral and bacterial infection. Using clinical vignettes, the use of these hematology parameters will be evaluated. The importance of rapid turnaround time, the impact on treatment decisions, and patient outcome in these clinical scenarios will also be highlighted.

Objectives:1. Describe the clinical presentation and laboratory work up utilized for patients with viral or

bacterial infection. 2. Explain why it is important to definitively distinguish between a viral infection and a bacterial

infection. 3. Discuss hematology laboratory parameters that may be useful in determining whether an infection

is viral or bacterial. 4. Using clinical scenarios and associated laboratory results, evaluate whether an infection is most

likely viral or bacterial.

22

2018 HAWAII CLINICAL LABORATORYCONFERENCE & EXHIBITS

Honolulu, HawaiiHonolulu Country Club

Meeting ScheduleTIME WEDNESDAY

May 16THURSDAY

May 17

7:00 AM Registration7:30 a.m. – 10:00 a.m.

Registration7:30 a.m. – 10:00 a.m.

8:00 AM Workshops8:00 a.m. – 9:30 a.m.

Workshops8:00 a.m. – 9:30 a.m.

9:00 AM

10:00 AM Workshops10:00 a.m.–11:30 a.m.

Workshops10:00 a.m.–11:30 a.m.

11:00 AM

Registration11:30 a.m. – 4:00 p.m.

Lunch11:30 a.m. – 1:30 p.m.

Exhibits11:30 a.m. – 5:30 p.m.

Registration11:30 a.m. – 4:00 p.m.

Lunch11:30 a.m. – 1:30 p.m.

Exhibits11:30 a.m. – 3:30 p.m.

12:00 PM

1:00 PM Workshops1:30 p.m. – 3:00 p.m.

Workshops1:30 p.m. – 3:00 p.m.

2:00 PM

3:00 PM Workshops3:30 p.m. – 5:00 p.m.

Workshops3:30 – 5:00 p.m.

4:00 PM .

5:00 PM

5:30 PM Workshop5:30 p.m. – 7:00 p.m.

ASCLS Business Meeting5:30 p.m. – 7:00 p.m.

23

2018 Hawaii Clinical Laboratory Conference Registration Form

REGISTER ON-LINE at www.HiClinLabConference.org using the Registration link.

LAST NAME__________________________FIRST NAME______________________

ADDRESS______________________________________________________________

CITY_____________STATE____ZIP CODE___________HOME PHONE__________

EMPLOYER___________________BUS.PHONE_____________EMAIL___________

ASCLS/CLMA/ASM Membership No.________________ EXP. DATE__________[Please circle] NOTE: Out of state members –please provide photocopy of current membership card

Early Bird Rates (Deadline: Received by April 20, 2018) Student/Retired MemberOne Full Day Workshop $100 $60Wednesday evening only (no lunch) 25 25

Regular Rates (Received April 21, 2018 to May 17, 2018)One Full Day Workshop $ 125 $60

Please enroll me in the following workshop(s):Wednesday May 16, 2018

8:00 – 9:30 amWorkshop #

10:00 – 11:30 amWorkshop #

1:30-3:00 pmWorkshop #

3:30-5:00 pm Workshop #

5:30-7:00 pm Workshop #

Fees$

Thursday May 17, 20188:00 – 9:30 am

Workshop #10:00 – 11:30 amWorkshop #

1:30-3:00 pmWorkshop #

3:30-5:00 pm Workshop # $

Total$

Forms of Payment:

Check made payable to CLMA Aloha Conference (enclose copy of completed form) Credit Card: payment via online registration at www.HiClinLabConference.org

Pay Pal accepts the following credit cards:Visa MasterCard Discover American Express

REGISTRATION INFORMATION24

REGISTRANT CATEGORIES:

MEMBER is a current member of good standing of the American Society for Clinical Laboratory Science (ASCLS), the Clinical Laboratory Management Association (CLMA), or the American Society for Microbiology (ASM).STUDENT MEMBER is any person who is engaged at least half time in a recognized program leading to either an Associate or Bachelor degree in Clinical Laboratory Science (Medical Technology) or one who is in a recognized Clinical Laboratory internship program and meets MEMBER status defined above.RETIRED MEMBER is any person who is retired from the profession and meets MEMBER status defined above.NON-MEMBERS are encouraged to join ASCLS, CLMA, or ASM.On-Line application forms may be found at www.ascls.org or www.clma.org or www.asm.org.

REGISTRATION NOTES: Priority will be given to online registrants for workshops. Availability of workshops after the early bird deadline is not guaranteed. Full day workshop fees include registration and lunch. Wednesday evening workshop is included in Wednesday full day workshop fee. Wednesday evening only workshop does not include lunch and fee cannot be combined with another workshop

on the same day. No charge to attend exhibits.

FEES: Registration fees vary according to the number of workshops you plan to attend. Please indicate on the program registration form the proper registration fee for your level of participation. Full payment must accompany all registrations. Credit card numbers submitted with registration will be processed online. Returned checks will incur additional fees.Please complete the registration form online at www.HiClinLabConference.org using the Registration link. Payments are acceptable by credit card online, or by check mailed along with the printed registration form to the address below. Checks made payable to: CLMA Aloha Conference. Mail check and registration form to:

2018 HCLC c/o PAC/RIM Medical Technology & Supplies Corp.

1618 Silva StreetHonolulu, Hawaii 96819

DEADLINES: Early Bird Registration must be received by April 20, 2018. Regular rates will apply after the early bird deadline and are due by May 7, 2018. On-Site registration will also be available, but workshops and lunch cannot be guaranteed.

REFUNDS: Requests for refunds must be submitted to HCLC by May 7, 2018 in writing. No refunds will be made thereafter. Please allow approximately six to eight weeks for processing.

CONTINUING EDUCATION: ASCLS-Hawaii is an approved provider of continuing education programs in clinical laboratory science through the ASCLS P.A.C.E® Program. The listed courses are approved for CA licensed clinical laboratory scientists and personnel.

PARKING: Complimentary

HANDOUTS: Registrants will be responsible for downloading their handouts from the website www.HiClinLabConference.org. Registration confirmation notice will include username/password. Handouts will also be available via the Events XD App. Download the app from the Apple or Google store, create a log-in and password. Search for HCLC 2018 and select your sessions that you signed up for. Handouts will be uploaded prior to the conference. Wi-fi will be available at the conference, check the registration desk for the password.

ACCESSIBILITY ASSISTANCE: If you require assistance due to mobility, hearing, or sight impairment, you are encouraged to contact the HCLC at hawaiicls@gmail.com by April 18, 2018.

Please direct all registration inquiries to: 2018 HCLCEmail: hawaiicls@gmail.com or mail inquiries to:

2018 HCLCc/o PAC/RIM Medical Technology & Supplies Corp.

1618 Silva StreetHonolulu, Hawaii 96819

25

EXHIBITS

The CLMA – Aloha Chapter and the ASCLS-Hawaii invite the clinical laboratory community to come and visit the Exhibits area in the Main Dining Room of the Honolulu Country Club. Admission is free. View displays showing the latest instrumentation and products for clinical laboratories. Exhibits will once again be the highlight of the Hawaii Clinical Laboratory Conference. Plan to visit the exhibits when your morning workshop is done or before the afternoon presentations. Door prizes will be announced throughout the convenient exhibit hours on both days and pupus will be served as well.

You may have noticed corporate sponsorship designated for most of the workshops. Seek out those sponsoring companies on the exhibition floor and thank the representatives. Let them know you appreciate their support of the 2018 Hawaii Clinical Laboratory Conference and look forward to seeing them again the next year. This is a list of 2017 exhibitors. We expect these exhibitors and others to participate.

Abbott Diagnostics – POC Grenier Bio-OneAbbott Diagnostics Grifols USA LLC

Abbott Diagnostics - Molecular Hologic Inc.Advanced Instruments Illumina

Alere Immucor GammaAlpha-Tec Inova

ARUP Instrumentation LaboratoryASCLS Hawaii Life Technologies (Thermo Fisher)

Audit Microcontrols, Inc. Luminex CorporationBeckman Coulter Meridian Biosciences

Beckman Coulter Primary Care Division Nova BiomedicalBecton Dickinson PAC/RIM Medical Technology & SuppliesBinding Site, Inc. Panasonic Healthcare

BioFire Diagnostics QiagenBioMerieux Quest Diagnostics

Bio-Rad Quidel (part of Diagnostic Hybrids)College of American Pathology Radiometer America

Cardinal Health RemelCepheid Roche Diagnostics Molecular

CLMA Aloha Chapter Roche Diagnostics Chem/Blood gasDiagnostica Stago SciexFisher Healthcare Siemens Diagnostic HealthcareFocus Diagnostics Sysmex

Genmark Diagnostics ThermoFisher ScientificGen-Probe University of Washington

26

Directions toHonolulu Country Club

1690 Ala Puumalu St., Honolulu, HI 96818Diamond Head (East) Bound from Ewa

1) Drive on Highway 78 towards Pearlridge and Aiea.2) Take Exit #2: Moanalua Valley/Salt Lake/Red Hill.3) Proceed up the hill and come to the three-way stop.4) Go straight and proceed down the hill to another three-way stop.5) Turn right onto Ala Napunani Street.6) Go straight and take your first right, which will be Ala Hahanui Street.7) Follow the road until you reach the three-way stop.8) Turn right on Ala Puumalu Street.9) Honolulu Country Club is located at 1690 Ala Puumalu Street at the end of the road.

Directions toHonolulu Country Club

1690 Ala Puumalu St., Honolulu, HI 96818Ewa (West) Bound from Honolulu

1) Take H1 West to H201 towards Fort Shafter and Aiea, which becomes Highway 78.2) Take Exit #2: Moanalua Valley/Salt Lake/Red Hill.3) Take the immediate right on Puuloa Rd, that sign will read Moanalua Valley/Salt Lake.4) Take an immediate left, that sign will read Salt Lake.5) After turning left, merge into the right lane. You are now on Ala Napunani Street.6) You will come to a three-way stop. Go straight.6) Take the next right, which will be Ala Hahanui Street.7) Follow the road until you reach the three-way stop.8) Turn right on Ala Puumalu Street.

27

9) Honolulu Country Club is located at 1690 Ala Puumalu Street at the end of the road

28